The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials

The alpha-7 nicotinic acetylcholine receptor (α7 nAChR), consisting of homomeric α7 subunits, is a ligand-gated Ca(2+)-permeable ion channel implicated in cognition and neuropsychiatric disorders. Enhancement of α7 nAChR function is considered to be a potential therapeutic strategy aiming at amelior...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Taoyi, Xiao, Ting, Sun, Qi, Wang, Kewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687317/
https://www.ncbi.nlm.nih.gov/pubmed/29159020
http://dx.doi.org/10.1016/j.apsb.2017.09.001
_version_ 1783278934416162816
author Yang, Taoyi
Xiao, Ting
Sun, Qi
Wang, Kewei
author_facet Yang, Taoyi
Xiao, Ting
Sun, Qi
Wang, Kewei
author_sort Yang, Taoyi
collection PubMed
description The alpha-7 nicotinic acetylcholine receptor (α7 nAChR), consisting of homomeric α7 subunits, is a ligand-gated Ca(2+)-permeable ion channel implicated in cognition and neuropsychiatric disorders. Enhancement of α7 nAChR function is considered to be a potential therapeutic strategy aiming at ameliorating cognitive deficits of neuropsychiatric disorders such as Alzheimer's disease (AD) and schizophrenia. Currently, a number of α7 nAChR modulators have been reported and several of them have advanced into clinical trials. In this brief review, we outline recent progress made in understanding the role of the α7 nAChR in multiple neuropsychiatric disorders and the pharmacological effects of α7 nAChR modulators used in clinical trials.
format Online
Article
Text
id pubmed-5687317
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56873172017-11-20 The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials Yang, Taoyi Xiao, Ting Sun, Qi Wang, Kewei Acta Pharm Sin B Review Article The alpha-7 nicotinic acetylcholine receptor (α7 nAChR), consisting of homomeric α7 subunits, is a ligand-gated Ca(2+)-permeable ion channel implicated in cognition and neuropsychiatric disorders. Enhancement of α7 nAChR function is considered to be a potential therapeutic strategy aiming at ameliorating cognitive deficits of neuropsychiatric disorders such as Alzheimer's disease (AD) and schizophrenia. Currently, a number of α7 nAChR modulators have been reported and several of them have advanced into clinical trials. In this brief review, we outline recent progress made in understanding the role of the α7 nAChR in multiple neuropsychiatric disorders and the pharmacological effects of α7 nAChR modulators used in clinical trials. Elsevier 2017-11 2017-10-16 /pmc/articles/PMC5687317/ /pubmed/29159020 http://dx.doi.org/10.1016/j.apsb.2017.09.001 Text en © 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Yang, Taoyi
Xiao, Ting
Sun, Qi
Wang, Kewei
The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
title The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
title_full The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
title_fullStr The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
title_full_unstemmed The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
title_short The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
title_sort current agonists and positive allosteric modulators of α7 nachr for cns indications in clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687317/
https://www.ncbi.nlm.nih.gov/pubmed/29159020
http://dx.doi.org/10.1016/j.apsb.2017.09.001
work_keys_str_mv AT yangtaoyi thecurrentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT xiaoting thecurrentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT sunqi thecurrentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT wangkewei thecurrentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT yangtaoyi currentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT xiaoting currentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT sunqi currentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials
AT wangkewei currentagonistsandpositiveallostericmodulatorsofa7nachrforcnsindicationsinclinicaltrials

Ejemplares similares